AGP Executive Report
Last update: 3 hours agoNorway outbreak alert: Norwegian health officials are investigating a Yersinia enterocolitica O3 outbreak after samples from 15 people (May 26–June 15) point to a common source; confirmed cases share the same genotype and patients are being interviewed about food and exposure. Rare disease drug news: Neuren Pharmaceuticals’ Rett syndrome treatment Daybu (trofinetide) has received a positive CHMP opinion for EU marketing authorisation, with a final European Commission decision expected soon—potentially making it the first EU therapy for Rett neurobehavioral symptoms. Cancer trial update: AB Science reports completion of Step 3 in Phase 1 for AB8939 + venetoclax in refractory/relapsed AML, showing a 67% overall response rate and no dose-limiting toxicities in a small cohort. Health workforce focus: MUHAS (Tanzania) is rolling out ongoing career support for health students after a baseline assessment found gaps in career awareness and structured guidance. Sleep & wellbeing: A personal insomnia guide highlights practical strategies like consistent wake times and daylight, while noting that “sleep hygiene” alone may not be enough for long-term insomniacs. Environment & health: A new analysis warns offshore oil and gas expansion overlaps with marine protected areas and whale corridors, raising concerns for ocean health.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
